Top 5 Target	Count

PLK4(Polo like kinase 4)	32
EZH2(Histone-lysine N-methyltransferase EZH2)	9
PD-1 x PDL1	5
PDL1(Programmed death-ligand 1)	3
c-Met(Hepatocyte growth factor receptor)	3

152

Drugs associated with Shenyang Pharmaceutical University

Mitoxantrone Hydrochloride

Target

DNA x Top II

Mechanism

DNA inhibitors [+1]

Active Org.

ASKA Pharmaceutical Co., Ltd. [+8]

Originator Org.

Merck Serono SA

Active Indication

Acute Myeloid Leukemia [+10]

Inactive Indication

Adult Lymphoblastic Lymphoma [+12]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date31 Dec 1984

Berberine Chloride Hydrate

Target-

Mechanism-

Active Org.

Hubei Huazhong Pharmaceutical Co. Ltd. [+2]

Originator Org.

Hubei Huazhong Pharmaceutical Co. Ltd.

Active Indication

Diarrhea [+3]

Inactive Indication

Diabetes Mellitus, Type 2 [+8]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1981

Demethylcantharidin

Target-

Mechanism-

Active Org.

Shenyang Pharmaceutical University

Originator Org.-

Active Indication

Breast Cancer [+3]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Shenyang Pharmaceutical University

CTR20200305

/ RecruitingPhase 1IIT

去甲斑蝥素脂质微球注射液在实体瘤患者中的安全性、耐受性、药代动力学Ⅰ期临床研究

[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of norcantharidin lipid microsphere injection in patients with solid tumors

主要目的：观察去甲斑蝥素脂质微球注射液在人体中的安全性，确定其剂量限制性毒性（DLT）、最大耐受剂量（MTD），为后期临床研究推荐剂量。次要目的：评价去甲斑蝥素脂质微球注射液在人体的药代动力学特征，并与已上市的注射用去甲斑蝥酸钠进行对比，探讨脂质微球剂型所引起的药代及初步安全性变化。

[Translation]

The primary objective is to observe the safety of norcantharidin lipid microsphere injection in humans, determine its dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), and recommend the dose for later clinical studies. The secondary objective is to evaluate the pharmacokinetic characteristics of norcantharidin lipid microsphere injection in humans, and compare it with the marketed norcantharidin sodium for injection to explore the pharmacokinetic and preliminary safety changes caused by the lipid microsphere dosage form.

Start Date22 Sep 2020

Sponsor / Collaborator

Shenyang Pharmaceutical University

CTR20201906

/ RecruitingPhase 1/2

一项评价淋巴示踪用盐酸米托蒽醌注射液用于胃癌患者淋巴示踪的单盲、单中心、安全性、耐受性、药代动力学特征及初步疗效的剂量递增和剂量扩展的I期/IIa 期临床试验研究

[Translation] A single-blind, single-center, dose-escalation and dose-expansion clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of mitoxantrone hydrochloride injection for lymphatic tracing in patients with gastric cancer.

本试验的目的是探索淋巴示踪用盐酸米托蒽醌注射液对胃癌患者淋巴示踪的有效性、安全性和耐受性并确定试验用药物最优使用剂量范围，同时探索淋巴示踪用盐酸米托蒽醌注射液对胃癌患者的药代动力学特征，为III 期临床试验的用药剂量及评价指标提供合理依据。

[Translation]

The purpose of this trial is to explore the efficacy, safety and tolerability of mitoxantrone hydrochloride injection for lymphatic tracing in patients with gastric cancer and determine the optimal dosage range of the trial drug. At the same time, it is to explore the pharmacokinetic characteristics of mitoxantrone hydrochloride injection for lymphatic tracing in patients with gastric cancer, and to provide a reasonable basis for the dosage and evaluation indicators of the Phase III clinical trial.

Start Date01 Sep 2020

Sponsor / Collaborator

Shenyang Xintager Pharmaceutical Technology Development Co., Ltd.

[+2]

CTR20200992

/ CompletedPhase 1

盐酸小檗碱缓释胶囊在健康受试者中单次、多次给药及食物影响的安全性、耐受性及药代动力学的Ⅰ期临床研究

[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of berberine hydrochloride sustained-release capsules in healthy subjects after single and repeated administration and food effects

评价盐酸小檗碱缓释胶囊在健康受试者中单次、多次给药的安全性、耐受性，确定最大耐受剂量，剂量限制性毒性，确定Ⅱ期临床推荐剂量。观察空腹和进食状态下健康受试者单次口服盐酸小檗碱缓释胶囊药代动力学的差异。评价盐酸小檗碱缓释胶囊在健康受试者中单次、多次给药的药代动力学特征及临床应用的安全性。

[Translation]

To evaluate the safety and tolerability of berberine hydrochloride sustained-release capsules in healthy subjects after single and multiple administrations, determine the maximum tolerated dose, dose-limiting toxicity, and determine the recommended dose for Phase II clinical trials. To observe the differences in the pharmacokinetics of berberine hydrochloride sustained-release capsules in healthy subjects after a single oral administration between fasting and feeding. To evaluate the pharmacokinetic characteristics of berberine hydrochloride sustained-release capsules in healthy subjects after single and multiple administrations and the safety of clinical application.

Start Date27 May 2020

Sponsor / Collaborator

Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences

[+3]

100 Clinical Results associated with Shenyang Pharmaceutical University

0 Patents (Medical) associated with Shenyang Pharmaceutical University

22,136

Literatures (Medical) associated with Shenyang Pharmaceutical University

01 May 2025·Talanta

Acylhydrazone-derivated calix[3]carbazole: A chemodosimeter for the detection of both TBATB and Br2

Article

Author: Guo, Wanxin ; Yang, Peng ; Zhou, Jing ; Liu, Liangang ; Su, Siming

The detection of both Br₂ and its derivative of tetrabutylammonium tribromide (TBATB) is a very important issue concerning their biological toxicity but remains challenging. Fluorescent sensing is one of the few methods possessing both selectivity and sensitivity. Moreover, it could be able to be utilized in biological system, but rarely reported. In this paper, we synthesized an acylhydrazone-derivated calix[3]carbazole (Compd 2), which could not only serve as the fluorescent sensor for TBATB, with high selectivity over other tested halides, but also be used to monitor the process of TBATB's formation generated by mixing Br₂ and tetrabutylammonium bromide (TBAB). Furthermore, the 2/TBAB complex is able to detect Br₂ in solution, in solid state as well as within the cells. The mechanism study showed upon addition of TBATB, the ketal functional groups of 2 at its "bridge" were converted to be the keto, and thus emitting fluorescence. This chemodosimeter possessed excellent sensitity with the limits of detection (LOD) for Br₃^- and Br₂ are 104 nM and 458 nM, respectively. To the best of our knowledge, it is the first chemodosimeter for both Br₃^- and Br₂ on the basis of the mechanism of the ketal-to-keto conversion.

01 May 2025·Biomaterials

PPS-TLR7/8 agonist nanoparticles equip robust anticancer immunity by selectively prolonged activation of dendritic cells

Article

Author: Wang, Yongjun ; Solek, Nicholas C ; Zhang, Yingxi ; Wang, Yue ; Li, Bowen ; Xu, Zhaochu ; Li, Yicheng ; Liu, Hongzhuo ; Xu, Linyi ; Li, Ning

Checkpoint inhibitor therapies do not benefit all patients, and adjuvants play a critical role in boosting immune responses for effective cancer immunotherapy. However, their systemic toxicity and suboptimal activation kinetics pose significant challenges. Here, this study presented a linker-based strategy to modulate the activation kinetics of Toll-like receptor 7/8 (TLR7/8) agonists delivered via poly (propylene sulfide) nanoparticles (PPS NPs). By covalently binding small molecule TLR7/8 agonists to PPS NPs with different linkers, enhanced therapeutic efficacy is achieved while abrogating systemic toxicity. These results showed that an alkyl linker selectively prolong the activation of DCs. It avoided the extensive activation of other APCs, favoring the limitation of immune-related toxicities. This strategy exhibited significant anti-tumor activity in alkyl linked nano-TLR7/8 agonists treatment alone, and cytokine and immune cell profiling provided evidence of prolonged immune cell activation in the tumor microenvironment, with evidence of an increase in the frequency of tumor antigen-specific CD8⁺ T cells. This linker-based approach offers a promising strategy to optimize the delivery of nano-TLR7/8 agonists for cancer immunotherapy, potentially advancing the field toward improved clinical outcomes.

01 Apr 2025·Biomaterials

Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment

Review

Author: Zhang, Baoyue ; Yu, Jiang ; Wang, Yongjun ; Liu, Hongzhuo ; Li, Xin ; Huang, Ruiping ; Jiang, Yu

Increasing evidence has showed that tumorigenesis is closely linked to inflammation, regulated by multiple signaling pathways. Among these, the cyclooxygenase-2/prostaglandin E₂ (COX-2/PGE₂) axis plays a crucial role in the progression of both inflammation and cancer. Inhibiting the activity of COX-2 can reduce PGE₂ secretion, thereby suppressing tumor growth. Therefore, COX-2 inhibitors are considered potential therapeutic agents for cancers. However, their clinical applications are greatly hindered by poor physicochemical properties and serious adverse effects. Fortunately, the advent of nanotechnology offers solutions to these limitations, enhancing drug delivery efficiency and mitigating adverse effects. Given the considerable progress in this area, it is timely to review emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and therapy. In this review, we first outline the various antineoplastic mechanisms of COX-2 inhibitors, then comprehensively summarize COX-2 inhibitors-based nanotherapeutics for cancer monotherapy, combination therapy, and diagnosis. Finally, we highlight and discuss future perspectives and challenges in the development of COX-2 inhibitors-based nanomedicine.

100 Deals associated with Shenyang Pharmaceutical University

100 Translational Medicine associated with Shenyang Pharmaceutical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

103

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tongshuan Jiuxin Tablets	Angina, Stable More	Phase 3
Mitoxantrone Hydrochloride ( DNA x Top II )	Stomach Cancer More	Phase 3
Imidol Hydrochloride	Hepatitis B, Chronic More	Phase 2
Liposomal docetaxel ( Tubulin )	Pancreatic Cancer More	Phase 1
QBH-196 ( c-Met )	Advanced Malignant Solid Neoplasm More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis